Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  American Journal of Physiology

• Publication date

  1992-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1152/AJPHEART.1992.262.2.H374PMID 1539695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.

  1991cited by this paper
• The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen.

  1990cited by this paper
• Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits.

  1990cited by this paper
• A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.

  1990cited by this paper
• Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.

  1990cited by this paper
• Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.

  1990cited by this paper
• Platelets and thrombolytic therapy.

  1990cited by this paper
• Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.

  1989cited by this paper
• After coronary thrombolysis and reperfusion, what next?

  1989cited by this paper
• Coronary thrombolysis and the new biology.

  1989cited by this paper
• Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.

  1989cited by this paper
• A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.

  1989cited by this paper
• Anticoagulant activity of synthetic hirudin peptides.

  1989cited by this paper
• Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.

  1989cited by this paper
• Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.

  1989cited by this paper
• Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.

  1989cited by this paper
• Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.

  1988cited by this paper
• Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.

  1988cited by this paper
• Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.

  1988cited by this paper
• Potentiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator

  1987cited by this paper
• Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis.

  1987cited by this paper
• Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.

  1986cited by this paper
• Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.

  1986cited by this paper
• Platelet active concentration profiles near growing thrombi. A mathematical consideration.

  1986cited by this paper
• Effect of a Selective Thrombin Inhibitor MCI-9038 on Fibrinolysis In Vitro and In Vivo

  1986cited by this paper
• Effect of heparin on platelet aggregation

  1984cited by this paper
• Structure of heparins and their fragments.

  1984cited by this paper
• Actions and interactions of antithrombin and heparin.

  1975cited by this paper

• 2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics

  2022cites this paper
• Case Report: Successful Reperfusion of Pulmonary Thromboembolism Using tPA in a Cat

  2022cites this paper
• The Therapeutic Potential of Abcirximab (c7E3 Fab) in Percutaneous Transluminal Coronary Angioplasty

  2012cites this paper
• Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.

  2008cites this paper
• Molecular physiology of bestrophins: multifunctional membrane proteins linked to best disease and other retinopathies.

  2008cites this paper
• Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk

  2007cites this paper
• Two-step ion-exchange chromatographic purification of recombinant hirudin-II and its C-terminal-truncated derivatives expressed in Pichia pastoris

  2006cites this paper
• Looking chloride channels straight in the eye: bestrophins, lipofuscinosis, and retinal degeneration.

  2005cites this paper
• Comparison of Hirudin and Heparin

  2005cites this paper
• Modular design of a novel chimeric protein with combined thrombin inhibitory activity and plasminogen-activating potential.

  2002cites this paper
• Effective Use of BCH-2763, a New Potent Injectable Direct Thrombin Inhibitor, in Combination with Tissue Plasminogen Activator (tPA) in a Rat Arterial Thrombolysis Model

  1998cites this paper
• A strong thrombin-inhibitory prourokinase derivative with sequence elements from hirudin and the human thrombin receptor.

  1997cites this paper
• Prevention of Early Reocclusion after Thrombolysis of Copper Coil-induced Thrombi in the Canine Carotid Artery: Comparison of PEG-Hirudin and Unfractionated Heparin

  1996cites this paper
• Construction and structure-activity relationships of chimeric prourokinase derivatives with intrinsic thrombin-inhibitory potential.

  1996cites this paper
• Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog.

  1996cites this paper
• Antithrombotic effects of hirulog in a rat carotid endarterectomy model.

  1996cites this paper
• Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).

  1996cites this paper
• Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.

  1996cites this paper
• Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis).

  1995cites this paper
• Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model.

  1995cites this paper
• Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis.

  1995cites this paper
• Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.

  1995cites this paper
• Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial.

  1995cites this paper
• Inhibition of Arterial Thrombus Formation in Two Canine Models: Comparison of Ancrod, a Fibrinogen-Depleting Agent, the Thrombin-Inhibitor r-Hirudin, and the Glycoprotein IIb/IIIa-Receptor Antagonist Ro 43-8857

  1995cites this paper
• New thrombolytic agents and strategies.

  1995cites this paper
• 10 New thrombolytic agents and strategies

  1995cites this paper
• Combinaisons de proteines active sur le plan thrombolytique et d'anticoagulants, et leurs utilisations

  1995cites this paper
• A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.

  1994cites this paper
• Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. II. Adjunctive Therapy with r‐Hirudin

  1994cites this paper
• Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis.

  1994cites this paper
• Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.

  1993cites this paper
• Comparison ofHirudin andHeparin as Adjuncts toStreptokinase Thrombolysis ina CanineModelofCoronary Thrombosis

  1993cites this paper
• Effects of trimetazidine on in vivo coronary arterial platelet thrombosis

  1993cites this paper
• SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.

  1993cites this paper
• Thrombolysis in acute myocardial infarction.

  1993cites this paper
• Thrombin, Thrombin Inhibitors, and the Arterial Thrombotic Process

  1993cites this paper
• Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.

  1993cites this paper
• Combination of Inhibition of Thrombin and Blockade of Thromboxane A2 Synthetase and Receptors Enhances Thrombolysis and Delays Reocclusion in Canine Coronary Arteries

  1992cites this paper